Table 1.

Characteristics of the cancer patients with COVID-19 infection

Patient	Age	Sex	Cancer type	ECOG performance status	Cancer treatment	Time between last cancer treatment and first occurrence of COVID-19 symptoms (days)	Management of COVID-19 infection	Time between first occurrence of COVID-19 symptoms and resumption of anti-cancer therapy (days)	Last follow-up since COVID-19 infection (months)	Outcomes
Patient 1	49	M	Lung leiomyosarcoma with lung metastasis	1	Gemcitabine- dacarbazine (Third line)	1	Hospitalisation (7 days) Oxygen therapy Anticoagulation Steroids	27	6	Death of disease
Patient 2	21	F	Lung adenocarcinoma (ALK rearrangement) with brain, bone, lung and liver metastasis	1	Brigatinib (Third line)	0	Ambulatory supervision with phone calls	10	12	Alive
Patient 3	66	F	Lung adenocarcinoma with lung metastasis	2	Weekly Paclitaxel (Third line)	6	Hospitalisation (5 days) Oxygen therapy Anticoagulation Antibiotics	13	2	Death of disease
Patient 4	71	M	Lung adenocarcinoma with lung metastasis	2	Carboplatin- paclitaxel (First line)	1	Hospitalisation (12 days) Oxygen therapy Antibiotics Tocilizumab	63	12	Alive
Patient 5	85	F	Lung adenocarcinoma with node, pleural and lung metastasis	1	Gemcitabine- oxaliplatin (Second line)	9	Hospitalisation (6 days) Oxygen therapy	58	12	Alive

ALK = anaplastic lymphoma kinase.